Chapter 3: Retnagene

20 Questions | Total Attempts: 81

SettingsSettingsSettings
Please wait...
Laboratory Quizzes & Trivia

This quiz has been designed to test your knowledge of 2 laboratory-developed tests for age-related macular degeneration, RetnaGene AMD and RetnaGene LR. You have 1 hour to complete the quiz. A passing grade is a 90% or above.


Questions and Answers
  • 1. 
    The RetinaGene AMD test provides an absolute risk of progression for a patient at which intervals?
    • A. 

      2, 5, and 10 years

    • B. 

      1, 3, and 5 years

    • C. 

      2, 4, and 8 years

    • D. 

      None of theabove

  • 2. 
    Pick two benefits of knowing a patient's risk for advanced AMD with RetinaGene LR from the following: 
    • A. 

      Development of individualized disease management plan with risk level in mind

    • B. 

      Reduce the risk of disease occurence and recurrence in families at risk

    • C. 

      Reduce the risk of glaucoma

    • D. 

      Increased surveillance to identify first sign of AMD

  • 3. 
    True or False. The AAO recommends genetic testing to monitor the frequency of surveillance for patients with AMD. 
    • A. 

      False

    • B. 

      True

  • 4. 
    The RetnaGene LR is an LDT combining the following elements in assessing a patients absolute and lifetime risk of developing advanced dry or wet AMD: 
    • A. 

      Age, Family History , Phenotype

    • B. 

      Age, Average Life expectancy and Genotype

    • C. 

      Genotype, Phenotype, Age and Environment

    • D. 

      Current stage of AMD, Smoking Status and Genotype

  • 5. 
    The best candidate for RetnaGene AMD testing would be described as follows: 
    • A. 

      Anyone with a family history of AMD

    • B. 

      55 years or older, Caucasian, with preexisting early or intermediate AMD

    • C. 

      Smokers with advanced AMD

    • D. 

      55 years of older with a family history of AMD

  • 6. 
    RetnaGene LR results may be used to encourage patients to practice primary prevention methods, such as smoking cessation and eating a diet rich in zinc, omega-3 fatty acids, beta-carotene, and lutein/zeaxanthin 
    • A. 

      True

    • B. 

      False

  • 7. 
    The Simplified Severity Scale  is used to determine risk scores by: 
    • A. 

      Monitoring patients using a fixed surveillance schedule based on their stage of disease

    • B. 

      Determining a patients genotype result for each SNP tested

    • C. 

      Utilizing SNPs, alone and in combination with other patient information

    • D. 

      Comparing patient's risk profile with the risk profiles of all AREDS patients of the same grade

  • 8. 
    Which of the following statements are correct? Choose 2
    • A. 

      RetnaGene LR genotyping includes 12 SNPs associated with AMD

    • B. 

      RetnaGene AMD genotyping includes 12 SNPs associated with AMD

    • C. 

      RetnaGene LR genotyping includes 8 SNPs associated with AMD

    • D. 

      RetnaGene AMD genotyping includes 8 SNPs associated with AMD

  • 9. 
    Results of the  RetnaGene LR test are intended to:   
    • A. 

      Show the prevalence of advanced AMD in the United States

    • B. 

      Give the patient's absolute and relative risk of developing advanced AMD in an individuals lifetime

    • C. 

      Identify at-risk Caucasians, 55 years or older with early onset of AMD

    • D. 

      Manage patient's risk of progression so that vision may be preserved in both eyes

  • 10. 
    Which of the following is included in testing with RetnaGene AMD?
    • A. 

      Age, Genotype, Phenotype, and Environment

    • B. 

      Genotype, Age, Phenotype, and Average Life Expectancy

    • C. 

      Age, Genotype, Phenotype, and Family History

    • D. 

      Age, Average Life Expectancy, and Genotype

  • 11. 
    Which of the following is included in testing with RetnaGene LR?
    • A. 

      Age

    • B. 

      Average Life Expectancy

    • C. 

      Genotype

    • D. 

      All of the above

  • 12. 
    Which of the following statement is NOT correct?
    • A. 

      RetnaGene AMD tests risk of progressing to CNV.

    • B. 

      RetnaGene AMD tests risk of progressing to GA.

    • C. 

      RetnaGene LR tests risk of developing CNV.

    • D. 

      RetnaGene LR tests risk of developing GA.

  • 13. 
    Which study is the source of the patients in the RetnaGene validation study?
    • A. 

      Perlee

    • B. 

      Hannum

    • C. 

      AREDS

    • D. 

      Rotterdam

  • 14. 
    Which of the following statements is TRUE?
    • A. 

      Fixed surveillance is the best method of detecting early conversion to CNV.

    • B. 

      RetnaGene AMD research has shown that all AMD patients of the same AREDS Simplified Severity Scale grade should be followed on the same schedule in order to have the least missed conversions to CNV.

    • C. 

      RetnaGene AMD increases the visit burden for retina specialists in exchange for increased detection of early CNV.

    • D. 

      Risk-based surveillance may reduce the number of missed conversions to CNV by about 8%.

  • 15. 
    Smoking history is a very important component of the RetnaGene LR test.
    • A. 

      True

    • B. 

      False

  • 16. 
    Identifying a patient's risk of developing Wet AMD with RetnaGene AMD will allow the ECP to administer anti-VEGF treatments immediately.
    • A. 

      True

    • B. 

      False

  • 17. 
    ECP's can best leverage RetnaGene LR with
    • A. 

      Advanced AMD patients

    • B. 

      Family members of advanced AMD patients

    • C. 

      Advanced Dry AMD patients

    • D. 

      Their staff members

  • 18. 
    RetnaGene AMD assesses the median risk of a patient with AMD developing CNV.
    • A. 

      True

    • B. 

      False

  • 19. 
    Practical uses of RetnaGene AMD results include all of the following EXCEPT
    • A. 

      Optimize the monitoring schedule for an individual patient

    • B. 

      Assist the ECP in determining need for additional home monitoring devices

    • C. 

      Increased anti-VEGF treatments

    • D. 

      Improve patient compliance with vitamin therapies and lifestyle change recommendations

  • 20. 
    Who is going to be Number One in the Nicox Sales Force?